DIAMEDICA THERAPEUTICS INC's ticker is DMAC and the CUSIP is 25253X207. A total of 42 filers reported holding DIAMEDICA THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 7.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $2,376,000 | -20.6% | 1,176,344 | -1.7% | 1.10% | -11.0% |
| Q1 2022 | $2,993,000 | -32.8% | 1,197,245 | +0.2% | 1.24% | -39.3% |
| Q4 2021 | $4,456,000 | +570.1% | 1,194,670 | +620.7% | 2.04% | +574.9% |
| Q3 2021 | $665,000 | -64.4% | 165,775 | -60.5% | 0.30% | -69.0% |
| Q2 2021 | $1,869,000 | -80.0% | 419,942 | -59.0% | 0.98% | -80.7% |
| Q1 2021 | $9,364,000 | -2.8% | 1,023,409 | +7.7% | 5.06% | -31.4% |
| Q4 2020 | $9,633,000 | +98.2% | 950,000 | -17.1% | 7.38% | +45.8% |
| Q3 2020 | $4,861,000 | +4.9% | 1,146,470 | +71.5% | 5.06% | -43.6% |
| Q2 2020 | $4,632,000 | +100.4% | 668,430 | -19.0% | 8.97% | +267.1% |
| Q1 2020 | $2,311,000 | +8153.6% | 825,297 | +5921.9% | 2.44% | +8951.9% |
| Q3 2019 | $28,000 | -97.5% | 13,705 | -94.5% | 0.03% | -95.9% |
| Q1 2019 | $1,135,000 | – | 250,000 | – | 0.65% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 325,000 | $1,404,000 | 2.87% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 198,730 | $858,514 | 0.97% |
| Bleichroeder LP | 294,117 | $1,270,585 | 0.26% |
| EAM Investors, LLC | 270,419 | $1,168,210 | 0.22% |
| COOPERMAN LEON G | 875,993 | $3,784,290 | 0.20% |
| CATALYST FINANCIAL PARTNERS LLC | 36,267 | $156,673 | 0.06% |
| Legend Financial Advisors, Inc. | 1,000 | $4,320 | 0.00% |
| FIRST MANHATTAN CO. LLC. | 124,744 | $538,894 | 0.00% |
| Tower Research Capital LLC (TRC) | 6,240 | $26,957 | 0.00% |
| MASSMUTUAL TRUST CO FSB/ADV | 4,824 | $20,840 | 0.00% |